Blinking Dermatitis

Abstract

Repeated blanching and flushing of the skin, usually the nail bed, is often called Quincke sign. This sign is commonly related to aortic insufficiency, although it may be observed in the nail bed of normal individuals. Case report: Quincke sign manifested on the wrist of a young healthy man. The patient had self-treated with topical antibiotics and steroids for a second-degree burn, but then developed contact dermatitis followed by cellulitis. He presented to the emergency department with a “blinking” effect of the skin lesion. Conclusion: The “blinking” effect is the result of focal subcutaneous arterial dilatation in the zone of subcutaneous inflammation.

Quincke, quincke‐like and pseudo‐quincke signs: nosology of cutaneous phenomena

“…A variety of cutaneous lesions including plaques, bullae, dermatitis and keratoderma have been described as causing Quincke, Quincke-like and pseudo-Quincke signs with a blanching and/or pulsatile appearance. [1][2][3][4][5] Blanching or capillary pulsation is not present in all patients with these cutaneous lesions. The common underlying histopathologic abnormality in these cases, including the one reported by Robustelli-Test et al, is believed to be caused by an underlying inflammatory infiltrate with superficial cutaneous vessels.…”

“…The common underlying histopathologic abnormality in these cases, including the one reported by Robustelli-Test et al, is believed to be caused by an underlying inflammatory infiltrate with superficial cutaneous vessels. [1][2][3] The eponymic sign named in honour of Heinrich Irenaeus Quincke (1842-1922) was described in in his 1868 paper titled 'Beobachtungen € uber Capillar-und Venenpuls'. 6 Quincke identified in one or more fingernails the capillary pulse located between 'the border between a more whitish, blood-poor region and a redder, more intensely portion of the capillary system of the nail-bed'.…”

“…Some ML models are already sold directly to the public as mobile applications despite unknown performance in this domain. 2 We assessed a direct-to-consumer application available in Europe (termed Model1) and a model available for research purposes as a reference (Model2) in the diagnosis of MCC and amelanotic melanoma images.…”